Table 2a. The numbers (%) of highly asbestos-exposed (⩾5 million fibres), asbestos-exposed (1–<5 million) and non-exposed patients' lung tumours with lost (ratio <0.75), gained (ratio >1.3), or normal 2p DNA sequences.
Probe location | RP11-183P21 | RP11-963J22 | RP11-703K23a | RP11-347F1 | RP11-1114A19 | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2p21 | 2p21 | 2p16.3 | 2p16.3 | 2p16.2 | |||||||||||
n=82 | n=75 | n=134 | n=95 | n=54 | |||||||||||
Highly exp (n=31) | Exp (n=13) | Non-exp (n=38) | Highly exp (n=22) | Exp (n=15) | Non-exp (n=38) | Highly exp (n=41) | Exp (n=29) | Non-exp (n=64) | Highly exp (n=27) | Exp (n=20) | Non-exp (n=48) | Highly exp (n=18) | Exp (n=8) | Non-exp (n=28) | |
DNA status | |||||||||||||||
Lossb | 2 (6) | 0 (0) | 1 (3) | 0 (0) | 0 (0) | 1 (3) | 6 (15) | 2 (7) | 1 (2) | 5 (19) | 3 (15) | 4 (8) | 2 (11) | 3 (38) | 3 (11) |
Gain | 9 (29) | 4 (31) | 14 (37) | 14 (64) | 5 (33) | 17 (45) | 2 (5) | 4 (14) | 6 (9) | 2 (7) | 3 (15) | 8 (17) | 2 (11) | 1 (13) | 1 (3) |
Normal | 20 (65) | 9 (69) | 23 (60) | 8 (36) | 10 (67) | 20 (52) | 33 (80) | 23 (79) | 57 (89) | 20 (74) | 14 (70) | 36 (75) | 14 (78) | 4 (50) | 24 (86) |
Abbreviation: Exp=exposed.
The probe providing best differentiation between the asbestos-exposed and non-exposed patients' tumours. Fisher's exact test between non-exposed and exposed (⩾1 million, P=0.09), and between non-exposed and highly asbestos-exposed (⩾5 million, P=0.02).
The groups with the most significant difference are given in bold.